Weight loss study for adults with overweight or obesity
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests an investigational medication, called NNC0721-8060, to see how it works in people with excess weight (overweight or obesity). It may help with weight loss, but is still in early human testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 55 years old.
- Your body mass index (BMI) must be between 27.0 and 34.9.
- You must not have diabetes (an A1c level below 6.5%).
- You must be in generally good health, as judged by the study doctor.
- Women who can have children must use birth control and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medicine (semaglutide) to see if it helps adults with excess weight lose weight. It might offer an easier, pill-based treatment option for weight management.
This study tests a nasal spray containing semaglutide (a GLP-1 receptor agonist) to see if it helps adults who are overweight or obese lose weight. It may be an option if you have a BMI between 27 and 35 and have not used other weight loss medications recently.
This study tests a medication called semaglutide (a once-weekly injection) to help people with obesity lose weight. It is for adults who have already tried lifestyle changes without success.
This study tests whether a low dose of semaglutide (a once-weekly injection) can help obese adults without diabetes lose weight. Semaglutide works by reducing appetite and helping your body use food differently.
This study tests a weekly injection called semaglutide to see how well it helps people with obesity lose weight, compared to a similar approved medicine, Wegovy. It may be an option if you have struggled to lose weight in the past.
This study tests a new weekly injection (called NNC0487-0111) against an existing medicine (semaglutide) to see if it helps people with type 2 diabetes lose more weight. Together with standard diabetes care and lifestyle changes, you would receive the study medicine for about a year, and the study team will monitor your health and weight.
Hear when a new Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.